I de kliniske 12- ugers akut fase duloxetin forsøg med patienter med diabetisk neuropatisk smerte, blev der observeret en lille men statistisk signifikant stigning i faste blodglucose hos duloxetin- behandlede patienter.
In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetine- treated patients.